Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Hikma Will Buy Troubled Drug Unit
by Michael McCoy
June 2, 2014
| A version of this story appeared in
Volume 92, Issue 22
The London-based generic drug company Hikma Pharmaceuticals has agreed to acquire Boehringer Ingelheim’s U.S. injectable generic drug business for $225 million plus up to $75 million in milestone payments. Hikma also has an option to acquire Boehringer’s Ben Venue Laboratories facility in Bedford, Ohio. The plant, one of the largest sterile injectables manufacturing sites in the world, closed at the end of 2013 after a struggle with drug quality problems. Hikma plans to bring back products that were made in the Ohio plant by transferring output to its own facilities.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter